DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR PARNATE
All Clinical Trials for Parnate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00223691 | Treatment of Orthostatic Hypotension in Autonomic Failure | Recruiting | Vanderbilt University Medical Center | Phase 3 | 2002-03-01 | The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms. |
| NCT00296686 | Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression | Terminated | New York State Psychiatric Institute | Phase 4 | 2001-09-01 | This pilot study will assess the efficacy of several sequential pharmacological treatments for patients with Refractory Depression. |
| NCT00653393 | Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions | Completed | SFBC Ft. Myers, Inc | Phase 1 | 2004-10-01 | To compare the single-dose Bioavailability of Tranylcypromine and Parnate |
| NCT00653393 | Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions | Completed | Par Pharmaceutical, Inc. | Phase 1 | 2004-10-01 | To compare the single-dose Bioavailability of Tranylcypromine and Parnate |
| NCT01031810 | PET Biomarkers in Treatment Resistant Depression | Terminated | National Institute of Mental Health (NIMH) | Phase 4 | 2009-11-01 | The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population. |
| NCT01031810 | PET Biomarkers in Treatment Resistant Depression | Terminated | New York State Psychiatric Institute | Phase 4 | 2009-11-01 | The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Parnate
Clinical Trial Locations for Parnate
Trials by Country
Clinical Trial Progress for Parnate
Clinical Trial Phase
Clinical Trial Sponsors for Parnate
Sponsor Name
